The Pulse - May 2026

Greetings Readers! In this monthly edition, we examine 3 practice changing studies.

Help keep this newsletter free by exploring the link to our advertising partner this month, found at the bottom of this email.

1. Sepsis Gets Personal: SSC 2026 Trades Dogma for Nuance

   The 2026 Surviving Sepsis Campaign guidelines continue the slow pivot away from rigid protocolization and toward individualized resuscitation strategies. High-confidence shifts include moving away from qSOFA in favor of more sensitive screening tools like SIRS and MEWS, adopting age-conscious MAP targets (with lower targets [MAP >60] reasonable in older adults), and endorsing a more flexible approach to antibiotic timing — reserving the “within 1 hour” urgency primarily for shock or clearly probable sepsis. The guidelines also reinforce that fluids still come first for most hypotensive patients, though simultaneous vasopressors are acceptable in unstable shock, reflecting ongoing uncertainty rather than doctrinal certainty. Perhaps the most practice-changing addition is the recommendation to actively de-resuscitate after stabilization, acknowledging that the real danger sometimes begins after the fourth liter. Overall, the update reads less like a new gospel of sepsis care and more like critical care finally admitting that patients stubbornly refuse to follow algorithms. Prescott HC et al. Crit Care Med 2026 April

   Study Type: Surviving Sepsis Campaign updated guideline

   Link

2. CAP and Gown: When 3 Days of Antibiotics May Be Enough

   In a target trial emulation of more than 55,000 hospitalized patients with community-acquired pneumonia, carefully selected low-risk patients who achieved clinical stability by hospital day 3 did just as well with 3–4 days of antibiotics as with traditional ≥5-day courses. Mortality, readmissions, and C. difficile rates were essentially identical, suggesting that for some CAP patients, “clinically stable” may matter more than “day five.” The catch: only about 10% of patients met eligibility criteria. Still, the study adds fuel to the growing antimicrobial stewardship movement that shorter can be smarter — provided the patient looks better, thinks clearly, and vital signs have stopped auditioning for a rapid response call. The era of “finish the full week because we always do” continues to lose ground to individualized, physiology-driven care. Doumat G et al. Annals Int Med 2026 April

   Study Type: observational emulation of a target trial including 5,620 hospitalized (non-ICU) patients with CAP across 67 Michigan (USA) hospitals. Original data set included 55,000+ patients but only 10.1% met inclusion criteria, suggesting generalizability limitations. Study also funded by insurance company (Blue Cross Blue Shield)

   Link

3. Not All Clots Are Created Equal: Rethinking DVTs from the Waist Up

   The American Venous Forum has finally given upper-extremity DVT its own clinical identity, recognizing that treating arm clots like leg clots is anatomically tidy but etiologically naive. The 2026 guidelines establish three distinct subtypes — venous thoracic outlet syndrome–associated, catheter-associated, and non–catheter-associated DVT — each requiring a tailored diagnostic and management approach. Notably, D-dimer testing earns a split decision: useful for ruling out non–catheter-associated DVT (sensitivity >90%) but unreliable in catheter-associated cases (sensitivity ~50%), where it should be abandoned in favor of duplex ultrasound. Treatment centers on oral Xa inhibitors for a minimum of three months, with first-rib resection recommended for thoracic outlet syndrome cases and anticoagulation continued three months post-catheter removal. While the evidence base remains modest, these guidelines represent a meaningful step toward more precise, anatomically-informed venous management. Malgor RD et al. J Vasc Surg Venous Lymphat Disord 2026 July.

   Study Type: new guideline from the American Venous Forum

   Link

Thank you for reading! If you enjoyed this newsletter, please consider sharing with your colleagues.